Tech Company Financing Transactions
Procyrion Funding Round
Fannin, Bluebird Ventures and private investors joined a $57.7 million Series E funding round for Procyrion. The round was recorded on 2/5/2024.
Transaction Overview
Company Name
Announced On
2/5/2024
Transaction Type
Venture Equity
Amount
$57,700,000
Round
Series E
Investors
Fannin (Lead Investor)
Proceeds Purpose
The company intends to use the funds to support the ongoing DRAIN-HF pivotal IDE trial evaluating the Aortix� percutaneous mechanical circulatory support (pMCS) device in patients with acute decompensated heart failure (ADHF) who remain congested despite standard medical therapy (cardiorenal syndrome or CRS).
Company Information
Company Status
Private & Independent
Industry
Medical Devices & Instruments
Mailing Address
3900 Essex Ln. 850
Houston, TX 77027
USA
Houston, TX 77027
USA
Phone
Undisclosed
Website
Email Address
Overview
The Procyrion device consists of a small, continuous flow pump mounted within a self-expanding anchoring system. The device is advanced through a catheter in the femoral artery to the descending thoracic aorta. The self-expanding anchors deploy to fix the pump to the aortic wall.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Eric Fain
Chief Medical Officer
Reynolds Delgado
Chief Scientific Officer
Jason Heuring
VP - Product Management
Chris Durst
VP - Regulatory Affairs
Katherine Cox
VP - Regulatory Affairs
Elisabeth Neely
Browse more venture capital transactions:
Prev: 2/5/2024: Vektor Medical venture capital transaction
Next: 2/5/2024: Nauticus Robotics venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to record all VC transactions involving tech companies. All VC database entries reported here are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs